Prada Carlos E, Hufnagel Robert B, Hummel Trent R, Lovell Anne M, Hopkin Robert J, Saal Howard M, Schorry Elizabeth K
Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH; Center for Genomic Medicine and Metabolism, Fundación Cardiovascular de Colombia, Floridablanca, Colombia.
Division of Human Genetics, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; University of Cincinnati College of Medicine, Cincinnati, OH.
J Pediatr. 2015 Oct;167(4):851-856.e1. doi: 10.1016/j.jpeds.2015.07.001. Epub 2015 Jul 29.
To evaluate the utility of screening brain/orbital magnetic resonance imaging (MRI) in a large population of children with neurofibromatosis type 1 (NF1) over a 20-year period.
A retrospective analysis of clinical and imaging data from children with NF1 seen at a single center between 1990 and 2010 was performed.
During the 20-year study period, 826 individuals with NF1 (402 females, 424 males) ages 1-9 years were screened for optic pathway gliomas (OPGs) using brain/orbital MRI; 18% were identified with OPGs with a median age at detection of 3 years. Fifteen percent of patients with OPGs had radiologic or clinical progression requiring therapy. Children with chiasmatic and postchiasmatic tumors were more likely to require therapy compared with patients with prechiasmatic OPGs (P < .0001). Patients with visual deficits at the time of diagnosis were more likely to experience visual decline despite therapy when compared with patients treated based on radiologic progression (P < .012).
Our findings confirm that chiasmatic and postchiasmatic OPG in children with NF1 have the highest risk for progression and vision loss. Early identification of OPG by screening MRI prior to the development of vision loss may lead to improved visual outcomes. Children with negative brain and orbital MRI screening at age 15 months or later did not develop symptomatic OPGs.
评估在20年期间对大量1型神经纤维瘤病(NF1)儿童进行脑/眼眶磁共振成像(MRI)筛查的效用。
对1990年至2010年在单一中心就诊的NF1儿童的临床和影像数据进行回顾性分析。
在20年的研究期间,对826名年龄在1至9岁的NF1患者(402名女性,424名男性)进行了脑/眼眶MRI检查以筛查视神经通路胶质瘤(OPG);18%的患者被确诊患有OPG,确诊时的中位年龄为3岁。15%的OPG患者出现了需要治疗的影像学或临床进展。与视交叉前OPG患者相比,视交叉和视交叉后肿瘤的儿童更有可能需要治疗(P < .0001)。与基于影像学进展接受治疗的患者相比,诊断时存在视力缺陷的患者在接受治疗后更有可能出现视力下降(P < .012)。
我们的研究结果证实,NF1儿童的视交叉和视交叉后OPG进展和视力丧失的风险最高。在视力丧失发生之前通过筛查MRI早期发现OPG可能会改善视力预后。15个月及以后脑和眼眶MRI筛查结果为阴性的儿童未出现有症状的OPG。